Guardant Health, Inc. has signed an agreement with Janssen Biotech Inc. to pursue regulatory approval and commercialization of the Guardant360 CDx blood test as a companion diagnostic for amivantamab, an antibody that Janssen is developing for the treatment of non-small cell lung cancer (NSCLC).
With this strategic collaboration, the companies will work together to co-market their respective products in the US, Canada, Japan and...







